Featured Articles
-
Diving Into The Intricacies Of An Approach To Continuous Flow
2/24/2022
Ajinomoto Bio-Pharma's Dr. Bert Metten fields questions on continuous flow, including scale-up parameters, modeling approaches, reactor design and reaction optimization.
-
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement With AstraZeneca To Include Drug Product Manufacturing
3/30/2021
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, announced a manufacturing agreement expansion with AstraZeneca to include drug product manufacturing.
-
Ajinomoto Bio-Pharma Services Completes Acquisition Of Granules OmniChem Joint Venture In India
6/2/2020
Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that it has completed the acquisition of Granules OmniChem Private Limited, purchasing the remaining 50 percent ownership interest from its joint venture partner, Granules India Limited.
-
Continuous Flow Manufacturing Of Pharmaceutical Ingredients
11/25/2019
Strong growth is anticipated for continuous flow manufacturing of APIs as it offers important advantages over traditional batch manufacturing in terms of quality, safety, and sustainability of the overall process.
-
Prioritize Safety And Mitigate Risk In HPAPI Manufacturing
As highly potent active pharmaceutical ingredients become increasingly common across the industry, it is critical to work with partners who use a risk-based approach to ensure safety and quality.
-
How To Select The Ideal HPAPI Manufacturing Partner
To ensure the safety of personnel throughout the production of HPAPIs, manufacturers must effectively utilize containment and well-designed equipment.
-
The Paradigm Shift To Continuous Flow Processes: A Holistic View
Dr. Bert Metten, Tech. Dev. Manager at Ajinomoto Bio-Pharma Services, explores dangerous chemistries and continuous flow processes for the manufacture of safe, efficacious, cost-effective products.
-
Leveraging CDMOs In Pharma's Drive Toward Net Zero
Environmental considerations in pharmaceutical manufacturing strategies have become increasingly important in the face of additional calls to address pollution and sustainability practices globally.
-
Rethinking Manufacturing Processes To Identify Green Opportunities
Reducing the carbon footprint of your pharmaceutical fine chemicals manufacturing process requires a shift from the traditional process development approach. Sustainability requires revolutionary changes.
-
Implement A Risk-Based Approach To Safely Manufacture HPAPIs
As interest in HPAPIs as powerful therapeutic mechanisms continues to grow, drug manufacturers must design thoughtful risk-based containment strategies to protect employees and ensure safety.